Previous Close | 22.37 |
Open | 22.24 |
Bid | 21.95 x 200 |
Ask | 22.12 x 200 |
Day's Range | 21.75 - 22.59 |
52 Week Range | 5.65 - 29.56 |
Volume | |
Avg. Volume | 815,856 |
Market Cap | 1.562B |
Beta (5Y Monthly) | 2.20 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.90 |
Earnings Date | Feb 13, 2025 - Feb 17, 2025 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.20 |
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the European Medicines Agency (EMA) h
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseasesSAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of preclinical data, including mec